Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

NEWS ABOUT >

Biotechnology

Clean Rooms

Clinical Trials

Consultants

Digitalization

Drug Discovery & Development

Engineering

Global Pharma

Industrial talks

Ingredients

Lab Equipment

Logistics & Distribution

Manufacturing

Market

Outsourcing

Packaging

Quality / GMP

Regulation

Safety

Last edition

All magazines
Subscribe to our magazine

News about "Relapsing Multiple Sclerosis (RMS) "

Novartis Remibrutinib Reduces Relapse Rates in Phase 3 RMS Trials

Novartis’ remibrutinib significantly reduces annualised relapse rates versus teriflunomide in phase 3 RMS trials, with a favorable safety profile and no liver safety signal.

Relapsing Multiple Sclerosis (RMS) | 02/09/2026 | By News Bureau

Roche's Fenebrutinib Delivers Strong Phase III results as a Potential First-in-Class BTK Inhibitor for Multiple Sclerosis

In the pivotal FENtrepid trial, Roche’s BTK inhibitor fenebrutinib demonstrated a meaningful reduction in disability progression in Primary Progressive Multiple Sclerosis (PPMS), performing at least on par with OCREVUS—the current standard and only approved treatment for PPMS.

Relapsing Multiple Sclerosis (RMS) | 15/11/2025 | By Dineshwori | 396

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members